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Abstract 
Objectives: To describe the clinical characteristics, treatment response and genetic findings in the 
largest cohort of patients with syndrome of undifferentiated recurrent fever (SURF).  
Methods: Clinical and genetic data from patients with SURF were extracted from the Eurofever 
registry, an international web-based registry that retrospectively collects clinical information on 
patients with autoinflammatory diseases. 
Results: In this study 202 patients were included. Seven patients had a chronic disease course, 195 
patients had a recurrent disease course. The median age at disease onset was 4.6 years. Patients had 
a median of 12 episodes per year, with a median duration of 4 days. In 25 patients relatives were 
affected as well. Most commonly reported symptoms were arthralgia (n=125), myalgia (n=95), 
abdominal pain (n=98), fatigue (n=120), malaise (n=112), and mucocutaneous manifestations 
(n=139). In 17 patients genetic variants were found in autoinflammatory genes. These patients more 
often had affected relatives compared to patients without genetic variants (p=0.002). Most patients 
responded well to NSAIDs, corticosteroids, colchicine and anakinra. Complete remission was rarely 
achieved with NSAIDs alone.  
Notable patterns were found in patients with distinctive symptoms. Patients with pericarditis (n=12) 
were older at disease onset (32.3 years), and had fewer episodes per year (3.0/year) compared to 
other patients. Patients with an intellectual impairment (n=8) were younger at disease onset (2.2 
years) and often had relatives affected (28.6%). 
Conclusion: This study describes the clinical characteristics in the largest cohort of SURF patients. 
Patients with genetic variants found more often had relatives affected. 
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Key messages: 
What is already known about this topic?  
 Individuals with undifferentiated recurrent fever represent the majority of patients approaching 
the services devoted to the diagnosis and management of autoinflammatory diseases. 
What does this study add?  
 This study provides a detailed description of the clinical characteristics of largest cohort of 
patients with undifferentiated recurrent fever, along with known genetic data and response to 
treatment. 
How might this impact on clinical practice or future developments?  
 The detailed description of patients with specific symptoms can be used to identify similar 
patients in other centers and will aid future research regarding the identification of new 
autoinflammatory diseases 
 
Introduction 
Systemic Autoinflammatory diseases (SAIDs) are disorders characterized by periodic or persistent 
activation of the innate immune system in the absence of infection or autoimmunity. In monogenic 
SAIDs this is caused by mutations in a single gene.1 The best-characterized monogenic SAIDs are 
familial Mediterranean fever (FMF), cryopyrin associated periodic syndromes (CAPS), tumor necrosis 
factor-receptor associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD).2,3 
Other SAIDs, such as periodic fever, aphthous stomatitis, pharyngitis, adenitis (PFAPA) syndrome or 
Behҫet’s disease are multifactorial; multiple genes may be involved, but there is no single genetic 
cause. Clinical diagnostic criteria are available for these diseases.4,5 However, approximately 50% of 
patients with recurrent inflammation do not fit the clinical picture of any well-defined  SAID and do 
not have pathogenic mutations causing a known hereditary SAID.6, 7 This group of patients is said to 
have ‘undefined SAIDs’. Undefined autoinflammatory syndromes characterized by recurrent febrile 
episodes were named ‘syndrome of undifferentiated recurrent fever’ (SURF).8 Despite the ambiguous 
classification of this condition, individuals with SURF represent the majority of patients approaching 
the services devoted to the diagnosis and management of SAIDs.    
Characteristics of patients with SURF had not been extensively described in current literature. This 
might be due to the rarity of SAIDs, hampering sufficient patient numbers for research. To overcome 
this problem an international network for the study of SAIDs was established, the Eurofever 
Project.9,10 Beside the well-defined SAIDs, the Eurofever Project also collects clinical information on 
patients with undefined SAIDs, including SURF, providing a sufficient cohort for our study. 
This paper describes the clinical characteristics of the largest cohort of patients with SURF, along with 
known genetic data and response to treatment.  
 
Methods 
Eurofever registry 
Data of patients with SURF were collected from the Eurofever undefined SAID cohort. To enrol 
patients as undefined SAID in the registry, other confounding conditions (well-defined SAIDs 
including PFAPA, infectious, autoimmune, neoplastic) should have been reasonably excluded.  
Data entered before the 2th of November 2016 from the Eurofever registry (Executive Agency for 
Health and Consumers project no. 2007332), which has been collecting retrospective patient data 
since November 2009, were extracted.10 Ethical committee approval and informed consent was 
obtained in all participating centers. Detailed epidemiological, demographic and clinical data were 
collected anonymously.  
 
Inclusion and exclusion criteria 
Patients of which clinical information was available were included in this study. Patients were 
excluded from analysis if there was no evidence of increased acute phase reactants during episodes, 
or if there was no fever reported.  
Additional data were collected from patients with a clinical picture consistent of a defined SAID 
according to the Federici criteria, but without genetic analysis performed on the associated gene.11 
Centers of these patients were asked if further genetic analysis was performed since registration. 
Patients were excluded from analysis if genetic analysis revealed a defined SAID or if they received 
another diagnosis explaining their symptoms.   
 
Clinical and genetic information 
The clinical characteristics included the disease pattern (defined by either recurrent acute episodes, 
chronic disease or chronic with acute exacerbations), disease manifestations and response to 
treatment. Clinical manifestations were reported by the entering physician as being present never, 
sometimes/often or always during episodes. Treatment response was graded as complete (absence 
of clinical manifestations with normalization of inflammatory markers), partial (general amelioration 
of the clinical picture but not complete normalization of the clinical manifestations and/or systemic 
inflammation), or failure (lack of response). Information on molecular genetic analyses regarding the 
main SAIDs was collected. Genetic variants were classified as being pathogenic, likely pathogenic, of 
uncertain significance, likely benign or benign.12,13 Only pathogenic or likely pathogenic variants and 
variants of uncertain significance were noted in this study and were regarded as genetic variants in 
further analyses.14 Patients with (likely) pathogenic variants were included in this study as SURF if 
these were present on only one allele of a gene involved in autosomal recessive disease. 
 
Statistical analysis 
Categorical variables were described as frequencies and percentages. Numeric variables were 
reported as the median and interquartile range (IQR). To compare dichotomous variables with 
interval or ordinal variables the Mann-Whitney U test was performed. Correlations between two 
dichotomous variables, or a dichotomous variable and a nominal variable were assessed using the 
Chi-squared or Fisher’s exact test. The Spearman’s rank correlation was performed to assess 
differences between two interval variables or between interval and ordinal variables.  
The threshold for statistical significance was p<0.05. Statistical analysis was performed with IBM 
Statistical Package for the Social Sciences (SPSS) version 24. 
 
Results 
Patient inclusion 
In total, 337 patients were collected from the Eurofever registry. Patients came from 30 different 
centers. Clinical information was available for 235 patients. Patients were excluded when 
inflammatory markers were not elevated during fever episodes (n=26), or no fever was reported 
(n=3). Twenty-nine patients, coming from 10 centers, had a clinical picture consistent with a 
monogenetic SAID according to the Federici criteria, without genetic analysis performed on the 
associated gene.11 For this reason, a specific query was raised to the enrolling centers, allowing 
additional information for 24 patients. Thirteen patients had genetic analysis performed on the 
associated genes. One patient, who clinically classified as MKD, had pathogenic mutations in the MVK 
gene. Furthermore, 3 patients were diagnosed with diseases other than their clinical classification: 
systemic juvenile idiopathic arthritis (n=2) and ARPC1B-combined immunodeficiency (n=1). These 4 
patients were excluded from further analysis (Figure 1).  
 
Baseline characteristics 
Patients came from 17 different countries. Most patients came from Italy (n=110) and the United 
Kingdom (n=21). A complete list of the countries of residence is shown in supplementary table 1. 
Almost half of the patients were female (48%). The median age at disease onset was 4.6 years (IQR 
1.3-13.0)(Figure 2A). Thirty-eight patients had a disease onset in adulthood. 
 
Episode characteristics 
Seven patients had a chronic disease course, 18 patients had a chronic disease course with recurrent 
acute exacerbations, 177 patients had a disease course with recurrent episodes. Patients with 
recurrent episodes had a median of 12.0 episodes per year (IQR 4.0-15.0), with a median duration of 
4.0 days (IQR 3.0-7.0)(Figure 2B,2C). An irregular disease pattern was more frequently seen than a 
regular disease pattern (55.0% vs. 39.1%). A minority of patients (14.4%) reported specific triggers for 
disease episodes, including emotional stress and infection (Figure 2D). Clinical manifestations for 
patients with chronic and recurrent disease course are summarized in Table 1. Most commonly 
reported symptoms were arthralgia, myalgia, abdominal pain, fatigue, malaise and mucocutaneous 
manifestations.  
 
Treatment response 
NSAIDs and steroids were frequently used during attacks. NSAIDs were beneficial in 89/119 patients, 
but were rarely completely effective. Steroids were beneficial in 95/114 patients (45 complete, 50 
partial response). With colchicine therapy 9/52 patients had a complete response, and 23 had a 
partial response. Thirteen patients got treated with anakinra, 5 had a complete response, 3 had a 
partial response. Methotrexate was given in 11 patients, with a complete response in 2 and a partial 
response in 5 patients. Adenoidectomy and/or tonsillectomy had limited effect; 8/9 
adenotonsillectomies, 2/2 tonsillectomies and 1/2 adenoidectomies were ineffective. Figure 2E 
summarizes the responses to treatment.  
Comparing treatment response to other clinical information, we found that patients with a good 
response to NSAIDs or colchicine had a shorter episode duration (p=0.022 and p=0.024, respectively) 
compared to poor responders. In addition, a regular pattern of febrile episodes was more often 
described in patients with a good response to steroids or colchicine (p=0.041 and p=0.001, 
respectively). Patients with a good response to anakinra had a lower episode frequency (p=0.037), 
were older at disease onset (p=0.018) and more often had an irregular disease pattern (p=0.018) 
compared to patients with a moderate or bad response to anakinra. 
 
Family history 
Twenty-five patients had affected relatives. In 13 patients first degree relatives were affected. Three 
patients had multiple relatives affected. Within our cohort 2 patients were related to each other: 2 
sisters from Italy with a disease onset at 1 year and 12-13 attacks/year with a duration of 3 days. 
Common features of these sisters were a recurrent disease course, exudative pharyngitis, bilateral 
enlarged cervical lymph nodes, fatigue and malaise.  
Patients with relatives affected were significantly younger at disease onset and more often had a 
regular disease pattern (65.2% vs 33.1%, p=0.005) compared to patients without relatives affected 
(2.0 vs 5.9 years, p=0.006). Furthermore, genetic variants were more often found in patients with 
relatives affected (30.4% vs. 5.8%, p=0.002).  
 
Genetic characteristics  
Analysis of one or more SAID-related genes was performed in 168 patients (83,2%), either by 
complete gene screening, screening of most relevant exons or screening of most relevant point 
mutations. In total, 17 patients carried pathogenic variants, likely pathogenic variants or variants of 
uncertain significance. Two patients had a genetic variant in the NLRP3 gene, 8 in the MEFV gene, 2 
in the MVK gene, 5 in the TNFRSF1A gene and lastly, 1 patient had a variant in the NOD2 gene (Table 
2). No variants were reported in the PSTPIP1, NLRP12, CECR1, or IL1RN gene. One patient had 
variants found in two genes, the p.R92Q variant in the TNFRSF1A gene and the p.V198M variant in 
the NLRP3 gene.  
 
Clinical classification criteria 
When applying the Federici criteria, the majority of the patients (n=133, 66%) did not classify 
clinically for any of the major periodic fever syndromes.11 Sixty-four patients classified as clinically 
compatible with one hereditary periodic fever: 24 TRAPS, 12 CAPS, 14 FMF and 14 MKD. In addition, 
5 patients scored positive for multiple diagnoses: TRAPS and CAPS, TRAPS and MKD, CAPS and FMF, 
TRAPS and CAPS and MKD. Most patients had genetic analysis performed, in total 5 variants were 
found in the associated genes. Notably, in 13 patients genetic analysis of the associated gene was not 
performed (Figure 3). 
 
Distinctive manifestations 
More distinctive manifestations were reported in 51 patients (Table 3); most frequently reported 
were seizures (n=13), pericarditis (n=12), intellectual impairment (n=8) and bone 
alteration/deformity (n=5). A detailed description for these more severely affected patients can be 
found in supplementary table 2.   
Two groups of patients stood out. First, patients with pericarditis (n=12) were older at disease onset 
(32.3 vs. 4.0 years, p<0.001) and had a lower episode frequency (3.0 vs. 12.0/year, p=0.001), which 
was more often reported as irregular (10/12 vs. 94/171, p=0.005). Patients with pericarditis often 
reported arthralgia (6/12), myalgia (6/12), and abdominal pain (3/12). In 3 of 10 tested patients 
genetic variants were found; twice the p.R92Q variant in the TNFRSF1A gene and once the p.A744S 
variant in the MEFV gene.  
Secondly, patients with an intellectual impairment (n=8) were younger at disease onset (2.2 vs. 4.9 
years, p=0.030). Their median episode duration was 4.5 (3.0-6.3) days, they had a median of 12.0 
(5.5-15.8) episodes per year and in 28.6% relatives were affected, this did not differ from other 
patients. The following symptoms were more frequently reported in patients with an intellectual 
impairment: abdominal pain (100% vs. 47.8%, p=0.048), headache (87.5% vs. 35.3%, p<0.001) and 
generalized lymph node enlargement (57.2% vs. 9.9%, p<0.001). Seven of these patients had genetic 
analyses performed, all without genetic variants found. 
 
 
Discussion 
We describe the largest cohort of patients with SURF reported so far, enabling us to provide a broad 
description of the clinical characteristics, the genetic characteristics and the treatment response. 
 
An advantage of our study is the standardized and elaborate list of symptoms, which yields a 
comprehensive clinical picture of the patients. In addition to fever, most commonly reported 
symptoms were rather non-specific: arthralgia, myalgia, abdominal pain, mucocutaneous 
manifestations, fatigue and malaise. Arthralgia, myalgia and mucocutaneous manifestations were 
frequently reported in other smaller cohorts of patients with undefined periodic inflammation as 
well.15,16,17,18,19 Abdominal pain was frequently seen in another study with patients with a paediatric 
age at onset, but was not frequently reported in studies where patients had an adult age at onset.16 
Fatigue and malaise were reported by more than half of our patients, but were only mentioned in 
one other study.19 As fatigue and malaise are generally often encountered by patients with rheumatic 
diseases, an underreporting of these symptoms in other cohorts seems to be the most likely 
explanation of this discrepancy.19,20 
 
Most of our patients had a disease onset before the age of 5 years. However, even though a relevant 
number of patients with an adult-onset have been included, a selection bias could have decreased 
the average age of onset, due to an overrepresentation of paediatric centers in the Eurofever 
project. In other studies the age of disease onset varied from 4-43 years. 15,16,17,18,19 
 
As in most of the defined SAIDs, the vast majority of patients in our cohort had a favourable response 
to NSAIDs, steroids, colchicine, and anakinra, but patients rarely achieved complete response with 
NSAIDs alone.21,22,23,24 Contrary to the good effect observed in PFAPA syndrome, tonsillectomy and/or 
adenoidectomy were rarely effective in patients with SURF.22,23 Nonetheless, we cannot exclude a 
reporting bias, as physicians tend to enrol patients with a long-standing or difficult-to-treat disease 
course and thus leave out patients with a complete response to NSAIDs, tonsillectomy and/or 
adenoidectomy.  
 
We have found a correlation between the presence of genetic variants and a positive family history 
of (undefined) SAIDs. Whether this represents a causal relation is uncertain. One might reason that 
these genetic variants, although not by themselves pathogenic, could contribute to 
autoinflammation in combination with environmental triggers or other (epi)genetic factors. 
However, there may be mere confounding by indication as patients with a positive family history 
might have been more likely to undergo genetic testing. Furthermore, the method of genetic 
screening varied among patients and this registry was not designed for in-depth analyses of family 
history nor disease aetiology. Laboratory experiments and population-based genetic studies are 
necessary to define a causal relation between genetic variants and autoinflammation. Moreover, 
genetic screening was often limited, both in the number of genes tested and the proportion of the 
individual genes that was sequenced.  Hence, genetic diagnoses might have been missed, because 
the relevant genes or the relevant regions of the affected gene were not tested. Similarly, somatic 
mosaicism for autosomal dominant mutations would not have been detected. 
 
Many patients in our cohort classified positive with the Federici clinical score.11 However, over 75% 
of these patients had negative genetic results on the associated gene. This shows that patients with 
SURF resemble defined SAID patients, confirming the difficulty in differentiating between SURF and 
defined SAID on clinical grounds alone. Therefore, patients with recurrent inflammation should 
undergo thorough genetic screening.  
Unfortunately, 19% of the patients with a positive clinical score did not have genetic analysis 
performed on the associated gene. It should be noted that some patients were registered before the 
Federici criteria became available, therefore possibly less genetic tests were ordered. We reached 
out to the centers for additional data. This resulted in the exclusion of 4 patients for having received 
a different diagnosis, one patient had the SAID compatible with the clinical score. We cannot exclude 
with certainty that some patients within our cohort did have defined SAIDs or other diagnoses 
explaining their symptoms, especially for those who had not underwent thorough genetic screening. 
Therefore, we want to stress the importance of thorough diagnostics. The age of sequential single 
gene analysis is over. Patients with SURF deserve whole exome sequencing, where and when 
available and affordable. 
 
Looking at patients with distinctive manifestations, we found that patients with pericarditis, in line 
with published data concerning idiopathic recurrent pericarditis, had a disease onset in adulthood 
and a low episode frequency.25 However, patients with pericarditis in our cohort seem to form a 
specific cluster, since they also often suffered from musculoskeletal symptoms and abdominal pain, 
usually not reported in typical recurrent pericarditis.26 This could mean that these patients either 
display an extension of the spectrum of idiopathic recurrent pericarditis, or they form a distinct 
entity. Secondly, patients with an intellectual impairment often had relatives affected and were 
young at disease onset. Possibly these patients form a distinct entity on their own as well. 
Supplementary table 2 can be used to identify similar patients in other centers with distinctive 
symptoms. 
 
A limitation of our study is its retrospective design. As mentioned previously, we cannot exclude a 
bias in the selection of patients entered in the registry, favouring patients with more severe disease. 
An additional selection bias was introduced by the design of this analysis, excluding patients with 
normal acute phase proteins. Furthermore, for some patients parts of the clinical variables were 
missing as they were not retraceable from their clinical charts and, as mentioned previously, not all 
patients had thorough genetic analysis performed. More importantly, the lack of prospective follow-
up data hampers conclusions regarding outcome and long-term therapy response in these patients. 
As mentioned in previous Eurofever reports, the treatment response is also difficult to interpret due 
to the possibility that the natural disease course or simultaneous use of other drugs influenced the 
response to therapy.22 
 
In conclusion, we provide the first detailed description of the clinical characteristics of the largest 
international cohort of patients with SURF. This protean group of patients represents one of the most 
frequent subset observed in the daily practice of autoinflammatory disease clinics.6, 7Despite the 
large variability of this heterogeneous group of patients, the availability of a relevant number of 
affected individuals allowed to identify some interesting clues. A relevant proportion of the patients 
had other affected family members, A whole exome sequencing approach would be appropriate in 
such families in order to identify possible new genes. Moreover, some distinctive manifestations (like 
pericarditis or intellectual impairment) could allow the identification of novel SAID clinical clusters, 
possibly related to specific genes.  
In this study we described the characteristics of patients with SURF as a single group. However, 
different underlying causes for autoinflammation are undoubtedly present in this cohort. Future 
research, combining extensive genetic data with functional and phenotypic data, is likely to provide 
insight in genotype-phenotype relation, leading to the eventual identification of new SAIDs within 
this group.27 
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Figure 1. Flowchart of included patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Additional data were collected from 24/29 patients with a clinical picture consistent with a monogenetic SAID according 
to the Federici criteria
11
, without genetic analysis performed in the associated gene 
 
 
 
 
Exclusion: 29 patients 
- Inflammatory markers not elevated: n=26 
- No fever: n=3 
 
Eurofever registry: 
337 patients  
 
Additional data collection: 24 patients* 
Exclusion: 4 patients  
- Other explanation inflammation: n=4 
 
Total included: 
202 patients 
 
Clinical information available: 
235 patients  
 
Figure 2. Disease characteristics, medication response 
 
Other triggers were travel (1), teething (1), surgery (1), constipation (1), heath (1). 
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Table 1. Clinical manifestations during episodes 
 Chronic disease course (7)       Recurrent disease course patients (195)
 # 
 
n (%)^ 
 
n (%)^ Always         
 
Sometimes/often 
 Mucocutaneous 5     (71%) 134     (69%)  
    Apthous stomatitis 1     (14%)    10    (5%)* 47    (25%)** 
    Erythematous pharyngitis 1     (14%)    6      (3%)* 47    (25%)** 
    Exudative pharyngitis 0    6      (3%)* 30    (15%)** 
    Maculopapular rash 4     (57%)    10    (5%)* 29    (15%)** 
 Gastro-intestinal 2     (29%) 113     (58%)  
    Abdominal pain 2     (29%)    25    (13%)* 71    (36%)** 
    Vomiting 0    8      (4%)* 40    (21%)** 
    Diarrhea 1     (14%)    2      (1%)* 35    (18%)** 
 Musculoskeletal 7     (100%) 130     (67%)  
    Arthralgia 6     (86%)    31    (16%)* 88    (45%)** 
    Myalgia 6     (86%)    19    (10%)* 70    (36%)** 
    Oligoarthritis 1     (14%)    3      (2%)* 11    (6%)** 
 Ocular 1     (14%) 32       (16%)  
    Conjunctivitis 1     (14%)    0       19    (10%)** 
    Periorbital edema 0    1      (1%)* 10    (5%)** 
 Lymphoid 5     (71%) 96       (49%)  
    Enlarged cervical lnn 1     (14%)    22    (11%)* 59    (30%)** 
    Hepatomegaly 1     (14%)    8      (4%)* 19    (10%)** 
    Splenomegaly 1     (14%)    6      (3%)* 19    (10%)** 
 Cardio-respiratory 2     (29%) 34       (17%)  
    Chest pain 1     (14%)    3      (2%)* 23    (12%)** 
    Pericarditis 1     (14%)    1      (1%)* 10    (5%)** 
 Neurological 2     (29%) 82       (42%)  
    Headache 2     (29%)    23    (12%)* 51    (26%)** 
    Morning headache 0        3      (2%)* 23    (12%)** 
 Genito-urinary 0 14       (7%)  
    Urethritis/cystitis 0    0 7      (4%)** 
    Gonadal pain 0      1      (1%)* 2      (1%)** 
 Constitutional 7   (100%) 194     (>99%)  
    Fatigue 5     (71%)    35    (18%)* 80     (41%)** 
    Malaise 5     (71%)    35    (18%)* 72     (37%)** 
Clinical manifestations of all patients, separated for patients with a chronic disease course and recurrent disease course. In 
grey: number of patients that reported at least one symptom of that organ system. In white: most commonly reported 
symptoms of that organ system. For patients with a recurrent disease course the separate symptoms are split into in always 
(left column) or sometimes/often present during episodes (right column).  
# 
Patients with recurrent disease course and chronic disease course with recurrent acute exacerbations. 
^ percentage of total with chronic or recurrent disease course (7 or 195 patients)  
*Always present during episodes, ** sometimes/often present during episodes  
lnn=lymph nodes, n=number of patients.  
 
  
Table 2. Genetic characteristics 
N.= number of patients. class= classification 
* genetic classification:  3= uncertain significance, 4= likely pathogenic, 5= pathogenic. Patients with pathogenic mutations only had one 
mutation in the MEFV gene.  
 
  
  Molecular analyses     
  
 
N. 
tested 
 
Complete 
gene 
screening 
 
Most 
relevant 
exons 
Most 
relevant 
point 
mutations 
 
 
 
Unknown 
 
N. 
variants 
found 
 
 
 
Variants  
 
 
Genetic 
class* 
MEFV 118 34 70 4 10 8 p.A744S      
p.E148Q     
p.K25R  
p.R761H 
p.S339F 
p.V726A  
3 
3 
4 
4 
3 
5 
NLRP3 40 18 15  7 2 p.R488K 
p.V198M 
3 
3 
TNFRS1A 125 28 89  8 5 p.R92Q 3 
MVK 80 41 28 1 10 2 p.T356M 3 
NOD2 9 7 2   1 p.R702W/SNP8  3 
NLRP12 6 3 1  2 0   
PSTPIP1 3 1 2   0   
CECR1 1 1    0   
IL1RN 1 1    0   
Figure 3. Clinical classification criteria and genetic outcome  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This figure shows the patients who fulfilled the clinical classification criteria for a hereditary periodic fever syndrome.
11
 The third column (nr. genetic analyses)  displays the number of patients 
with genetic analyses performed of the associated gene.  
* Variants found in the associated genes: FMF p.A744S and p.V726A; MKD p.T356M; TRAPS p.R92Q  
 
 
 
 
 
TRAPS 
CAPS 
FMF 
MKD 
28  
16  
15  
16  
        n. positive   n. genetic analyses  n. variants in 
    Classification    classification   performed   associated gene  
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10  
12 
11 
2* 
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2* 
0 
Table 3. Distinctive manifestations in 51 patients 
  
N.  
 
 
 
N. 
Musculoskeletal 8 Gastro-intestinal 8 
     Bone alteration/deformity 5      Aseptic peritonitis 4 
     Flexion contractures 4      Gastro-intestinal ulcers 4 
     Osteitis 2      Gastro-intestinal bleeding 1 
     Osteolytic lesions 2      Intestinal occlusion 2 
     Muscular atrophy 3      Peritoneal adhesions 1 
     Hyperostotic lesions 1      Gut perforation 1 
Neurological 25 Cardio-respiratory 16 
     Seizures 13      Pericarditis 12 
     Intellectual impairment    8      Venous thrombosis 1 
     Aseptic meningitis 2      Cardiomyopathy 0 
     Cranial neuropathy 3      Arterial thrombosis 1 
     Peripheral neuropathy 3      Pulmonary fibrosis 
     (mild;severe) 
3 
(2;1)      Hydrocephalus 2 
     Cerebellar syndrome 1   
Mucocutaneous 4 Ocular 1 
     Genital ulcers 2      Retinal vasculitis 1 
     Pyoderma gangrenosum 1  Other 2 
     Necrotic lesions extremities 1      Macrophage activation syndrome 1 
       Death  1 
N. =number of patients 
 
 
  
Supplementary table 1.Countries of residence  
 
Argentina    (n=3)  
Croatia    (n=3) 
Czech Republic    (n=4) 
France    (n=18)  
Germany    (n=1) 
Iceland    (n=1) 
Italy     (n=110)  
Latvia     (n=2) 
Lebanon    (n=1) 
Norway    (n=1) 
Romania    (n=6) 
Russia     (n=3) 
Serbia and Montenegro (n=2) 
Slovenia    (n=1)  
Spain    (n=4) 
The Netherlands   (n=21) 
United Kingdom   (n=21) 
  
Supplementary table 2. 51 patients with distinctive manifestations 
 
 
Pt 
 
Age onset 
in years 
 
Attacks  
/year 
Attack 
duration 
(days) 
 
 
Distinctive manifestations 
1 
 
0.07 6 1 Death due to cardiovascular insufficiency, seizures, peripheral 
neuropathy 
2 
 
0.3 14 4 Bone alteration, flexion contractures, gastro-intestinal bleeding, 
seizures, mental retardation 
3 1.3 8 7 Bone alteration, osteolytic lesions, osteitis, hyperostosis 
4  8.4   Bone alteration, osteolytic lesions, osteitis, muscular atrophy 
5 
 
9.6 12 3 Bone alteration, muscular atrophy 
6 6.6   Flexion contractures, muscular atrophy, necrotic lesions at 
extremities 
7 
 
0.9 24 7 Flexion contractures, seizures, gastrointestinal ulcers, aseptic 
peritonitis, occlusion 
8 2.7 25 2 Hydrocephalus, seizures, sensorineural hearing loss, cerebellar 
syndrome, cranial neuropathy, arterial thrombosis, mild 
pulmonary fibrosis 
9 3.6   Mild mental retardation, aseptic meningitis, seizures 
10 0.7   Mild mental retardation, aseptic peritonitis, pyoderma 
gangrenosum, gastro-intestinal ulcers,  
11 0.8 10 7 Mild mental retardation, aseptic peritonitis,  
12 34.4   Pericarditis, aseptic peritonitis 
13 10.3 1  Pericarditis, peripheral neuropathy 
14 3.5 9  Gut perforation, peritoneal adhesions, occlusion 
15 38.7 5 3 Retinal vasculitis 
16 11.3   Flexion contractures 
17 16.2 12 1 Hydrocephalus,  
18 5.9 4  Aseptic meningitis 
19 37.8 3 2 Peripheral neuropathy 
20 11.3 12 10 Cranial neuropathy 
21 23.6 9 13 Cranial neuropathy 
22 0.3   Pulmonary fibrosis 
23 0.7   Pulmonary fibrosis 
24 11.2 4 8 Venous thrombosis 
25 9.6 1 21 Gastro-intestinal ulcers 
26 14.1 12 15 Gastro-intestinal ulcers 
27 19.2 5 3 Ulcers genitalia 
28 45.0 18 5 Ulcers genitalia 
29 6.8 12 21 Macrophage activation syndrome 
 
 
 
Pt 
 
Age onset 
Range  
(Mdn) 
Attacks 
/year 
Range 
(Mdn) 
Attack 
duration  
Range 
(Mdn) 
 
 
 
Distinctive manifestations 
30-
37 
0.03 - 7.0 
(1.7) 
5-20 
(12) 
3-13 
(5) 
Seizures 
38-
41 
0.0 - 8.3 
(3.8) 
4-18 
(11) 
3-6 
(4) 
Mental retardation 
42-
51 
8.0 - 56.6 
(32.3) 
2-16 
(3) 
2-18  
(6) 
Pericarditis 
Mdn=median. Pt=patient 
 
